Company intelligence / Profile preview

Hunterian Medicine

Baltimore, Maryland, United Stateshunterian.com ↗
Ownership
Private
Development stage
Other
01

Overview

Hunterian Medicine is developing a patented CRISPR delivery platform using a single AAV vector with bidirectional promoter for efficient in vivo gene editing; awarded Therapeutics Development Award by Cystic Fibrosis Foundation for cystic fibrosis program.

Therapeutic areas
PulmonologyRare Diseases
Modalities
CRISPR-based therapyGene therapy
Industry
Biotech
02

Drug pipeline

1 asset

Hunterian Medicine CFTR gene therapy

Preclinical
03

Partnerships

Cystic Fibrosis FoundationInscripta

Beyond the preview

Go deeper on Hunterian Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hunterian Medicine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call